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Abstract
The success of siRNA-based therapeutics highly depends on a safe and efficient delivery of siRNA into the cytosol. In this study,
we post-modified the primary amines on dendritic polyglycerolamine (dPG-NH2) with different ratios of two relevant amino acids,
namely, arginine (Arg) and histidine (His). To investigate the effects from introducing Arg and His to dPG, the resulting poly-
plexes of amino acid functionalized dPG-NH2s (AAdPGs)/siRNA were evaluated regarding cytotoxicity, transfection efficiency,
and cellular uptake. Among AAdPGs, an optimal vector with (1:3) Arg to His ratio, showed efficient siRNA transfection with
minimal cytotoxicity (cell viability ≥ 90%) in NIH 3T3 cells line. We also demonstrated that the cytotoxicity of dPG-NH2
decreased as a result of amino acid functionalization. While the incorporation of both cationic (Arg) and pH-responsive residues
(His) are important for safe and efficient siRNA transfection, this study indicates that AAdPGs containing higher degrees of His
display lower cytotoxicity and more efficient endosomal escape.
Introduction
Since the discovery of RNA interference (RNAi) and aware-
ness of its role in posttranscriptional gene silencing, tremen-
dous efforts and capital have been devoted to the development
of therapeutics based on this pathway [1]. So far, there are at
least 22 RNAi-based drugs in clinical trials and many more are
being developed [1]. Although a direct delivery of “naked”
siRNA or chemically modified oligonucleotides [2] has been
studied, delivery vectors are typically required for efficient
siRNA delivery in vivo due to unmodified siRNA’s low
stability towards endogenous enzymes, poor cellular uptake,
and its immunogenic potential [3].
Among the different polymeric vectors, polycationic
dendrimers and related structures have found wide application
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in gene/siRNA delivery [4]. This is because the synthesis of
dendrimers and dendritic polymers under controlled conditions
results in defined structures with low dispersity. Moreover, the
tree-like structure of such polymers provides multivalent
positions for functionalization and interaction with DNA/
siRNA.
Dendritic polyglycerol (dPG) can be synthesized on a kilogram
scale by a one-step, ring-opening polymerization of glycidol
with controllable sizes and degrees of branching [5]. Addition-
ally, dPG has multiple groups for further functionalization, high
chemical stability, and good biocompatibility in vitro and in
vivo [6-8]. All these characteristics make dPG an ideal scaffold
for a broad range of applications from anti fouling [9] to
biomedical purposes [6] such as anti-inflammatory [10] and
anticancer therapy [11,12].
Previously a number of cationic polymers like chitosan [13-15],
PEI [16], and PAMAM [17] have been post-modified with histi-
dine (His) or arginine (Arg) groups. The introduction of histi-
dine groups has been beneficial for improving the endosomal
release properties [18], and conjugation of arginine groups has
enhanced the transfection efficiency of cationic carriers [19,20].
Since the incorporation of either amino acid alone can improve
siRNA transfection, we hypothesized that functionalization with
both Arg and His may have a synergistic effect on siRNA trans-
fection. Moreover, the biocompatible nature of the amino acids
can possibly decrease the cytotoxicity of the resulting vectors.
Furthermore, Arg and His groups interact in histones, as natural
DNA binding proteins, via their positive residues with the nega-
tive phosphates groups of the DNA [21]. Here, we chose
dendritic polyglycerolamine (dPG-NH2) with moderate amine
loading (50% of all hydroxy groups on a 10 kDa dPG core) and
introduced both amino acids via amide coupling to mimic DNA
histones interactions.
In a recent study, our group demonstrated the potential of dPG-
NH2 with high amine loading (≥90%) for siRNA delivery in
vivo [22]. Moreover, it has been shown that dPG-NH2 90% is
able to efficiently downregulate the formation of several
proteins in vitro [23]. In spite of its high efficiency, the thera-
peutic window of dPG-NH2 90% is small and the cytotoxicity
increases at higher concentrations which limits its further appli-
cation. Here, we compare the potential of multivalent amino
acid functionalized dPGs (AAdPGs), for siRNA transfection
with dPG-NH2 90%. The initial in vitro results indicated that
AAdPGs were capable of mediating efficient siRNA delivery to
NIH 3T3 cells and induced comparable gene silencing to both
dPG-NH2 90% and lipofectamine RNAiMAX. In comparison
with dPG-NH2 90%, the new vectors showed reduced cytotoxi-
city and enhanced siRNA binding.
Results and Discussion
Functionalization of dPG-NH2 with arginine
and histidine
Amino acids have been implemented for the improvement of
gene/siRNA transfection using various strategies. Beside
peptide dendrimers [24,25], another strategy is to functionalize
the periphery groups on cationic vectors such as PLL [26], PEI
[16], and PAMAM [19]. In the current study, ≈50% of all
hydroxy groups on dPG (Mn = 8.4 kDa, PDI = 1.7) were
converted to amino groups according to an earlier published
procedure (Scheme S1, Supporting Information File 1) [27].
The high density of amines on dPG facilitates the introduction
of groups like amino acids by feasible strategies like amide
coupling. Here, we coupled both Arg and His groups in
different ratios to dPG-NH2 via the latter strategy (Scheme 1).
By introducing Arg on the dendritic scaffold, this group can
serve as a complexing agent and the surplus guanidium groups
with high affinity to phosphate groups can interact with the cell
membrane and improve the cellular uptake [28]. Additionally,
the histidine groups can facilitate tackling the endosomal
release problem by improving the polyplexes’s buffering
capacity [18]. Moreover, arginine and histidine groups can form
intermolecular hydrogen bonds with cell surface phosphate
groups. These interactions can induce cellular uptake of
AAdPG polyplexes. Therefore, four cationic vectors were
prepared by Arg and His functionalization of the dPG scaffold.
The list of all synthesized samples is presented in Table 1. The
samples were named based on their degree of Arg and/or His
functionalization on the polymeric backbone (dPG). The func-
tionalization degree for each polymer was determined by
comparing the peak integral of either the methylene groups of
arginine in high field or the imidazole ring of histidine in the
aromatic area (7.2–8.7 ppm) with the assignable dPG backbone
signal (Supporting Information File 1).
Variable composition of arginine and histi-
dine on dPG-NH2 50%
To investigate the effect from introducing both His and Arg to
dPG backbone on transfection efficiency, cytotoxicity, and
cellular uptake, two vectors were synthesized with equal (dPG-
13Arg13His) and different (dPG-8Arg30His) composition
ratios of both amino acids. Moreover, two further vectors with
either Arg (dPG-13Arg) or His (dPG-13His) were prepared to
examine the effect of each amino acid alone. The summary of
all dPG-based vectors is shown in Table 1.
siRNA Binding
The ability of AAdPGs to form complexes with siRNA was
examined by agarose gel electrophoresis retardation assay. The
electrophoretic mobility of the siRNA should have been
reduced or completely eliminated as a result of complexation
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Scheme 1: Synthesis of multivalent arginine and histidine functionalized dPG-NH2 50%. The depicted dPG-NH2 represents only a small idealized
fragment of a 10 kDa molecule.
Table 1: Summary of AAdPG vectors and their corresponding polyplex characterization.
Compound Zeta potential (mV)a diameter
(nm)b
PDIc (Arg) %d (His) %d Arg:His
dPG-NH2 50% 10.0 ± 0.2 124.1 ± 0.7 0.07 – – –
dPG-13Arg13His 10.9 ± 0.8 97.17 ± 0.87 0.13 13 13 1:1
dPG-13Arg 10.6 ± 0.9 60.04 ± 1.2 0.18 13 – –
dPG-13His 10.3 ± 0.3 70.23 ± 0.8 0.17 – 13 –
dPG-8Arg30His 11.0 ± 0.9 104.9 ± 0.45 0.18 8 30 ~1:3
aζ were measured at pH 7.4; bintensity distributions are reported; cPDI of polyplexes were determined by DLS; ddegree of functionalization on dPG
which were determined by 1H NMR spectroscopy.
with AAdPGs. As shown in Figure 1, all AAdPGs were able to
neutralize the negative charge of the siRNA and effectively
retard it at N/P ratios between 2 to 4. The binding capacity of all
vectors was slightly different from each other. The results of
this assay clearly display that all synthesized vectors were able
to form polyplexes with siRNA at low N/P ratios. Moreover, the
complex formation ability of the new vectors is comparable
with dPG-NH2 50% and 90%.
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Figure 1: Agarose gel electrophoresis retardation assay of AAdPGs/siRNA polyplexes. (A) dPG-13Arg13His, (B) dPG-13Arg, (C) dPG-13His,
(D) dPG-8Arg30His, (E) dPG-NH2 50%, and (F) dPG-NH2 90%. Naked siRNA always appears in the first lane. The numbers on the top of each lane
correspond to the different N/P ratios.
Average particle size and surface charges of
AAdPG/siRNA polyplexes
The appropriate particle size and surface charge are critical
characteristics of nanoplexes for efficient transfection [29].
Physicochemical characterization of AAdPG/siRNA poly-
plexes was conducted using dynamic light scattering (DLS).
Figure 2 shows the size distribution of dPG polyplexes (at N/P
ratio 10). The average size of all nanoparticles ranges from
60–100 nm. In general, the AAdPG/siRNA polyplexes were
smaller than the corresponding dPG-NH2 50%/siRNA poly-
plexes. Moreover, AAdPG complexes have a broader distribu-
tion of the final nanoparticles. The size of dPG-13Arg and dPG-
13His complexes was slightly smaller than the other dPG-based
vectors. The surface charge of the final nanoparticles was
comparable to the corresponding complexes of siRNA and
dPG-NH2 50% with terminal primary amines and about 10 mV.
The positive charge of the polyplexes is a further indication of
efficient siRNA complexation by AAdPGs. The results for the
size and zeta potential measurements of all vectors are summa-
rized in Table 1.
Figure 2: Size measurements of dPG-NH2 50% and AAdPGs/siRNA
complexes. Intensity distributions of all polyplexes are depicted.
Cell viability assay
The cytotoxicity of cationic polymers is mainly attributed to the
interactions of these polymers with the cell membrane and
depends on multiple factors such as molecular weight, the
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Figure 3: The result of MTT assay on a NIH 3T3 cell line transfected with AAdPG, dPG-NH2 50%, and 90%/siRNA polyplexes at different N/P ratios
with 100 nM siRNA concentration.
nature of the polymer surface, and its charge density [30]. The
results of the in vitro MTT assays on the NIH 3T3 cell line for
cytotoxicity evaluation of AAdPG polyplexes are shown in
Figure 3. These results were compared with dPG-NH2 50% as a
backbone and dPG-NH2 90%. Generally, these data indicates
that cytotoxicity of the final polyplexes is reduced by function-
alization of dPG-NH2 50% with Arg and His. Moreover,
decreasing the percentage of arginine on a dendritic scaffold
improved the cytotoxicity of the nanoplexes. Replacing the pri-
mary amines on dPG-NH2 with histidine groups would possibly
decrease the density of positive charge on dPG and increase cell
viability. The best cytotoxicity profile was observed for dPG-
8Arg30His with no considerable cytotoxicity (cell viability ≥
90%) up to N/P ratio 40 (Figure 3). We further compared the
cytotoxicity of dPG-8Arg30His with dPG-NH2 90% at N/P
ratio 30 where the efficiencies of both vectors were comparable.
Overall, these results demonstrated that dPG-8Arg30His is a
safer vector compared to dPG-NH2 90% (Figure 4).
In vitro transfection assay
The transfection efficiency of the AAdPGs was assessed in GFP
expressing NIH 3T3 cells (Figure 5). In general, the results indi-
cate that post-modification of the dendritic scaffold with Arg
and His improves the efficiency of siRNA transfection. The
most efficient vector in the knockdown of GFP (down regula-
tion of GFP expression to 38%) was obtained by converting
almost all primary amines on dPG to Arg and His with a 1:3
ratio. Moreover, by comparing the knockdown efficiency of
Figure 4: Cell viability versus transfection efficiency of dPG-8Arg30His
and dPG-NH2 90% at N/P ratio 30.
dPG-13Arg (without any histidine functionality) with all the
other vectors containing histidine, the critical role of histidine as
a buffering agent in enhancing transfection efficiency was
determined. Furthermore, we compared the result of our best
vector, dPG-8Arg30His, in terms of transfection with dPG-NH2
90%. These results indicate that dPG-8Arg30His (at N/P ratio
30) is as potent as dPG-NH2 90% in GFP knockdown while
maintaining its low cytotoxicity (Figure 4).
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Figure 5: Summary of transfection results versus viability of AAdPGs with various Arg and His composition ratio at N/P ratio 30.
Cellular uptake and confocal microscopy
The cellular uptake and localization of fluorescently labeled
siRNA/AAdPG complexes were quantified using flow cytom-
etry and confocal microscopy (Figure 6). By comparing the
cellular uptake of dPG-NH2 functionalized solely with either
histidine or arginine, for example, dPG-13Arg, one can clearly
see that Arg functionalization improved cellular uptake of both
dPG-NH2s. These results are in agreement with several studies
where the transmembrane function of arginine-rich peptides
was demonstrated [31,32]. Interestingly, there is a reverse effect
with respect to cellular uptake after functionalization of dPG-
NH2 with histidine. Notably, dPG-NH2s have shown a higher
cellular uptake than lipofectamine which is most probably due
to their high positive surface charge. These results in combina-
tion with transfection efficiency data suggest that the higher
transfection efficiency of histidine-functionalized vectors is
presumably due to their improved endosomal release.
Conclusion
We successfully post-modified dPG-NH2 with variable ratios of
Arg and His as mimicry of natural histones to afford safe and
efficient siRNA transfection. At certain ratios of Arg to His
(1:3) a multivalent cationic vector was obtained with compa-
rable transfection efficiency to lipofectamine (down regulation
of GFP expression to 37% at N/P ratio 40) and marginal cyto-
toxicity (cell viability ≥ 90% at N/P ratio 40). The efficiency of
this new vector is comparable to our well-studied vector, dPG-
NH2 90%. Post modification of dPG-NH2 with Arg and His did
not dramatically affect the physicochemical properties (particle
size and zeta potential) of the resulting vectors and their
nanoplexes but notably improved cell viability. This can be
attributed to the steric congestion around the amine groups and
more biocompatible surface functionalities after amino acid
functionalization of dPG-NH2. Compared to arginine, the intro-
duction of histidine more effectively reduced the cytotoxicity
and mediated an efficient endosomal escape. Moreover, by
comparing the result of cellular uptake with transfection effi-
ciencies, one can conclude that enhanced cellular uptake does
not guarantee by itself efficient siRNA transfection and that
incorporation of endosomal releasing groups like histidine




All chemicals and reagents were used as received from the
suppliers without further purification. Protected amino acids
and coupling reagents were purchased from abcr GmbH
(Karlsruhe, Germany). GelRedTM siRNA stain was purchased
from VWR (Radnor, PA). All cell culture media and fetal
bovine serum (FBS) was purchased from Invitrogen (Carlsbad,
CA). All siRNA used in this study was purchased from Ambion
(Carlsbad, CA) with Silencer® Select negative control siRNA
and Silencer®Cy™-3 labeled Negative Control siRNA used for
control and cellular uptake studies, respectively. Unmodified
Silencer® series siRNA was used for GFP silencing experi-
ments with the following sequence: sense 5’-CAAGCUGACC-
C U G A A G U U C T T - 3 ’  a n d  a n t i s e n s e  5 ’ - G A A C U -
UCAGGGUCAGCUUGCC-3’. All water used in the biological
experiments was nanopure water obtained from Barnstead
Nanopure Diamond (Waltham, MA). Both unmodified and
engineered NIH 3T3 cells expressing green fluorescence protein
(GFP) were kindly provided by Professor Young Jik Kwon
(Department of Chemical Engineering, UC Irvine, CA).
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Figure 6: Confocal images of NIH 3T3 cells treated with Cy3-siRNA/vector complexes: (A) naked siRNA, (B) lipofectamine, (C) dPG-13His, (D) dPG-
13Arg, and (E) mean Cy-3 fluorescence intensity of 3T3 cells treated with Cy3-siRNA/vector complexes assessed by FACS.
Functionalization of dPG-NH2 with arginine
(Arg) and histidine (His)
dPG (Mn = 8.4 kDa, PDI = 1.7) was prepared according to a
published procedure [33]. Fifty percent of all (~110) hydroxy
groups on dendritic polyglycerol were functionalized with
amino groups in a three-step protocol [27]. Briefly, the transfor-
mation was started with the mesylation of the hydroxy groups
on dPG. In the next step, the mesylated polyglycerol was
converted to polyglycerolazide. In the last step, azide function-
alities (N3) were reduced to primary amines (-NH2) via
Staudinger reduction (Scheme S1 in Supporting Information
File 1). For coupling both amino acids Arg and His to the
dendritic backbone, a solution of dPG-NH2, 30 mg (0.20 mmol
of amines) in methanol, was dried carefully under high vacuum.
The concentrated solution was then diluted in 1.5 mL DMSO.
The solution of dPG-NH2 in DMSO was left under vacuum for
30 min in order to remove methanol residues. Boc-protected
histidine and arginine were added to the solution of dPG-NH2 in
specific molar ratios. 1.2 Equivalents of BOP and DIPEA with
respect to the amino groups were added to the reaction subse-
quently. The reaction mixture was stirred at room temperature
overnight. This mixture was then transferred directly into a
dialysis tube of 1000 MWCO and dialyzed in methanol for
2 days. After removing methanol on a rotary evaporator
completely, the reaction mixture was treated with a mixture of
TFA/DCM/TIPS. The reaction was left running overnight to
complete the deprotection. After the deprotection step, dialysis
in 0.2 N solution of HCl for two days resulted in the formation
of products as chloride salt which were obtained as pale yellow
to brown solids by lyophilization. Noteworthy that each dPG
unit (10 kDa) has is about 100 hydroxy groups and therefore the
functionalization percentages always corresponds approxi-
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mately to the same number of functional groups per dPG. For
example, dPG-NH2 50% has about 50 NH2 groups per polymer
unit. The amino acid functionalization percentage of each
polymer was defined using 1H NMR analysis. 1H NMR
(400  MHz ,  D 2 O)  dPG-13Arg13His :  δ  =  1 .6  ( s ,
NHCH2CH2CH2CH, 2H), 1.9 (s, NHCH2CH2CH2CH, 2H),
3–4.5  (m,  dPG backbone,  NHCH2CH2CH2CH and
N H C H 2 C H 2 C H 2 C H N H 2 C O  o f  a r g i n i n e  g r o u p s ,
NH2COCHCH2C and NH2COCHCH2C of histidine groups),
7.4 (s, CHNHCHN, 1H of imidazole groups) and 8.7 (s,
CHNHCHN, 1H of imidazole groups) ppm. dPG-13Arg: δ = 1.6
(s, NHCH2CH2CH2CH, 2H), 1.9 (s, NHCH2CH2CH2CH, 2H),
3–4.5  (m,  dPG backbone,  NHCH2CH2CH2CH and
NHCH2CH2CH2CHNH2CO of arginine groups) ppm. dPG-
13His: δ = 3–4.5 (m, dPG backbone, NH2COCHCH2C and
NH2COCHCH2C of histidine groups), 7.4 (s, CHNHCHN, 1H
of imidazole groups) and 8.7 (s, CHNHCHN, 1H of imidazole
groups) ppm. dPG-8Arg30His: δ = 1.6 (s, NHCH2CH2CH2CH,
2H), 1.9 (s, NHCH2CH2CH2CH, 2H), 3–4.5 (m, dPG backbone,
NHCH2CH2CH2CH and NHCH2CH2CH2CHNH2CO of argi-
nine groups, NH2COCHCH2C and NH2COCHCH2C of histi-
dine groups), 7.4 (s, CHNHCHN, 1H of imidazole groups) and
8.7 (s, CHNHCHN, 1H of imidazole groups) ppm.
Gel electrophoresis
The binding of AAdPGs to siRNA was evaluated by agarose gel
electrophoresis retardation assay. Stock solutions of siRNA and
AAdPGs were prepared in phosphate buffer (10 mM, pH 7.4).
To a 2 µL solution of siRNA (4 µM), different amounts of
AAdPG compounds were added to achieve different N/P ratios
(the molar ratio between amine groups of dPGs to siRNA phos-
phate groups). The final volume of the mixture was adjusted to
12.5 µL by the same buffer solution. siRNA and AAdPGs were
incubated at room temperature for 30 min. After incubation,
2.5 µL of 6X orange gel loading dye was added to each sample.
10 µL of the final mixture was then loaded on a 1% agarose gel
with 1X GelRedTM. After filling the gel packets with poly-
plexes, electrophoresis was run in TAE buffer for 45 min at
60 V. The results were visualized under UV illumination.
DLS/Zeta
The size and zeta potential (ζ) of AAdPG/siRNA polyplexes
were measured by a Zetasizer Nano ZS analyzerTM with inte-
grated 4 mW He-Ne laser, λ = 633 nm (Malvern InstrumentsTM
Ltd, U.K.). Stock solutions of dPG samples and siRNA (50 µM)
in nanopure water were prepared. An appropriate amount of
each dPG sample was mixed with 2.85 µL siRNA (6 nmol
phosphate) solution. The mixtures were diluted to 100 µL and
after short vortexing were incubated for 30 min at rt. Subse-
quently, DLS measurements were recorded. The same mixture
from DLS measurements was taken and diluted with 0.8 µL
phosphate buffer (10 mM, pH 7.4). These samples were then
subjected to zeta potential measurements. The measurements
were repeated at least three times for each sample and the mean
values were reported.
MTT assay
Unmodified NIH 3T3 cells were seeded at a density of 5,000
cells per well in 96-well plates 24 h in advance. The culture
media was changed from 100 μL DMEM with 10% fetal bovine
serum (FBS) to 80 μL plain DMEM immediately before expo-
sure to the complexes. The dPG/siRNA complexes were
prepared by first diluting the siRNA to 1.5 μM with PBS
(10 mM phosphate, 10 mM NaCl, pH 7.4) and then adding the
proper amount of vector solution (5 mg/mL in ddH2O) to give
the desired N/P ratio and concentration. After 30 minutes incu-
bation at rt, 20 μL of the complex solutions were added to each
well to give a final volume of 100 μL per well. After 4 h incu-
bation, the media was replaced with 10% FBS/DMEM and the
cells cultured for another 48 h. To assess the viability, the
media was replaced with 50 μL DMEM solution containing
0.5 mg/mL MTT, followed by 4 h incubation at 37 °C. 100 μL
of DMSO was added to each well to dissolve the formazan and
the plate was incubated at 37 °C for 30 min with agitation. The
absorbance at 540 nm was measured using a plate reader and
the viability determined by comparison with untreated controls.
Transfection
NIH 3T3 fibroblast cells expressing GFP were seeded at a
density of 10,000 cells/well in 48-well plates 24 h in advance
and the culture media replaced with 200 μL plain DMEM
immediately prior to transfection. AAdPG/siRNA complexes
were prepared as described previously with either anti-GFP
siRNA or negative control siRNA. 50 μL of the complex solu-
tions were added to each well to give a final volume of 250 μL
per well. After 4 h incubation, the media was replaced with
10% FBS/DMEM and the cells cultured for another 48 h.
Before the analysis, cells were released from each well with
trypsin and harvested by centrifugation (5 min, 500G). GFP
fluorescence of transfected cells was measured on a Becton-
Dickinson LSR II flow cytometer with argon ion excitation
laser. For each sample, data representing 10,000 objects were
collected as a list-mode file and analyzed using FACSDivaTM
software (Becton Dickinson, version 6.1.3) and the percent
knockdown was calculated by comparing the mean fluores-
cence intensity of cells treated with vector/anti-GFP siRNA to
that of cells treated with complexes formed with the control
siRNA.
Cellular uptake study
For quantitative assessment of cellular uptake, negative control
siRNA labeled with Cy3 (siRNA-Cy3) was complexed with the
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vectors in PBS as described previously. Unmodified NIH 3T3
cells were seeded in 48-well plates and transfected with the
siRNA-Cy3/vector complexes following the same transfection
protocol used for GFP silencing experiments. Immediately after
the 4 h exposure to the transfection media, the cells were
trypsinized and collected via centrifugation. The transfected
cells were analyzed by FACS to determine the mean Cy3-fluo-
roscence of each sample.
Confocal microscopy
Unmodified NIH 3T3 fibroblast cells were seeded at a density
of 10,000 cells/well on an 8-well chamber slide (Lab-Tek,
Rochester, NY) 24 h before transfection. Cy3-labeled siRNA
was complexed with the vectors and the cells transfected with
the complexes following the previously described protocol.
After 4 h exposure to the transfection media, the media was
changed back to DMEM supplemented with 10% fetal bovine
serum. Confocal fluorescence spectroscopy was performed at
different time points after the transfection. The nuclei were
stained with Hoechst 33342 following the standard protocol.
The images were acquired using a Zeiss LSM 510 inverted
laser-scanning confocal microscope with a 40× numerical aper-
ture oil immersion planapochromat objective. A 559 nm
helium–neon laser, a SMD640 dichroic mirror, and a
575–620 nm band-pass barrier filter were used to obtain the
images of Cy3-labeled siRNA. Images of the stained nuclei
were acquired using a 780 nm two-photon excitation light, a
635 nm dichroic mirror, and a 655–755 nm band-pass barrier
filter. The two fluorescent images were scanned separately and
overlaid together with the differential interference contrast
image (DIC). The cells were scanned as a z-stack of two-dimen-
sional images (1024 × 1024 pixels) and an image cutting
approximately through the middle of the cellular height was
selected to present the intracellular siRNA localization.
Statistical analysis
All transfection studies were performed in triplicates; data were
expressed as mean ± SEM.
Supporting Information
Supporting Information File 1
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